Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03947970
Recruitment Status : Completed
First Posted : May 13, 2019
Last Update Posted : July 24, 2019
Sponsor:
Information provided by (Responsible Party):
Cara Therapeutics, Inc.

Brief Summary:
The objectives of this study are to evaluate the in vivo metabolite profiling and characterization of CR845 administered intravenously (IV) in patients on hemodialysis (HD) and in healthy subjects; and to determine the pharmacokinetics of radiolabeled [14C] CR845 administered as a single IV bolus in patients on HD and in healthy subjects.

Condition or disease Intervention/treatment Phase
Hemodialysis Healthy Drug: [14C] CR845 Phase 1

Detailed Description:
This is a Phase 1, open-label, single-radiolabeled dose, non-randomized study in 6 male patients on HD and 6 healthy male subjects. The study will consist of a Screening Period, a Study Period, and an End-of-Study assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects
Actual Study Start Date : January 17, 2019
Actual Primary Completion Date : April 6, 2019
Actual Study Completion Date : April 6, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: [14C] CR845
Subjects will receive a single dose of [14C] CR845 IV solution administered as an IV bolus on Day 1.
Drug: [14C] CR845
Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries [14C] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)




Primary Outcome Measures :
  1. Measure of the [14C] CR845 and total radioactivity (total [14C] CR845-equivalents) in plasma, urine, feces, and dialysate will be determined. [ Time Frame: Day 1 to up to 7 days post dose in healthy volunteers and Day 1 to up to 14 days post dose in patients on HD ]
  2. Extent of recovery of [14C] CR845 and radioactivity related to [14C] CR845 in plasma, urine, feces, and dialysate, as applicable, will be derived. [ Time Frame: Day 1 to up to 7 days post dose in healthy volunteers and Day 1 to up to 14 days post dose in patients on HD ]
  3. Cumulative amount of [14C] CR845 and [14C] CR845-equivalents in urine and feces over the collection period will be calculated. [ Time Frame: Day 1 to up to 7 days post dose in healthy volunteers and Day 1 to up to 14 days post dose in patients on HD ]
  4. Presence of possible CR845 metabolites will be assessed. [ Time Frame: Day 1 to up to 7 days post dose in healthy volunteers and Day 1 to up to 14 days post dose in patients on HD ]
  5. Quantitation of possible CR845 metabolites will be assessed. [ Time Frame: Day 1 to up to 7 days post dose in healthy volunteers and Day 1 to up to 14 days post dose in patients on HD ]

Secondary Outcome Measures :
  1. Frequency and severity of adverse events by treatment group [ Time Frame: Day 1 to up to 7 days post dose in healthy volunteers and Day 1 to up to 14 days post dose in patients on HD ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria for Healthy Subjects

  • Body mass index (BMI) within the range of 18 to 30 kg/m2, inclusive, and body weight not less than 75 kg;
  • Vital signs at Screening must be within the following ranges and stable (measured in sitting position after at least 5 minutes' rest);

    • Systolic blood pressure (SBP) ≥100 and ≤140 mmHg;
    • Diastolic blood pressure (DBP) ≥50 and ≤90 mmHg;
    • Heart rate (HR) ≥50 and ≤100 beats per minute (bpm).
  • Must be in good health as determined by past medical history, physical examination, ECG, vital sign assessments, and clinical laboratory tests at Screening. Any subjects with abnormalities noted at Screening or at any time before dosing on Day 1 must be approved by the Investigator and Medical Monitor.

Key Inclusion Criteria for patients on HD

  • If taking concurrent medications, must be on a stable dose for at least 14 days prior to dosing and the dosing regimen should remain stable for the duration of the study;
  • Prescription dry body weight of ≥75 kg and ≤135 kg at Screening;
  • Must be receiving HD 3 times weekly and have been on dialysis for at least 3 months prior to Screening;
  • For a minimum of 1 month before Day 1, must have stable controlled blood pressure that in the Investigator's opinion will not interfere with study conduct;
  • Demonstrated adequate dialysis measurements (at least two Kt/V measurements ≥1.2 or two urea reduction ratio [URR] measurements ≥65%) during the 3 months prior to Screening

Key Exclusion Criteria:

  • Has a concomitant disease or any medical condition that, in the opinion of the Investigator, could pose undue risk to the patient, impede completion of the study procedures, or would compromise the validity of the study measurements, including, but not limited to:

    • Known or suspected history of alcohol, narcotic, or other drug abuse, or substance dependence within 12 months prior to Screening;
    • Significant systolic or diastolic heart failure (eg, New York Heart Association Class IV congestive heart failure [Appendix 1]);
    • Severe mental illness or cognitive impairment (eg, dementia);
    • Any other relevant acute or chronic medical or neuropsychiatric condition.
  • History of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator;
  • Use of any beverages and foods containing alcohol, quinine (tonic water), grapefruit, broccoli, Brussels sprouts, Seville oranges, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine from 48 hours prior to dosing with study medication without evaluation and approval by the Investigator;
  • Use of any over-the-counter (OTC) medication (including nutritional or dietary supplements, herbal preparations, or vitamins, chapparal, comfrey, germander, gin bu huan, kava, pennyroyal, skullcap, St. John's Wort, or valerian) within 7 days prior to dosing with study medication;
  • Use of any new prescription medication from 14 days prior to dosing with study medication without evaluation and approval by the Investigator;
  • Has been treated with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine) within 30 days prior to dosing with study medication, and that, in the Investigator's judgment, may impact subject safety or the validity of the study results;
  • Positive results for human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg);
  • Is a healthy subject with positive results for hepatitis C virus (HCV) antibody at Screening. Note: Subjects with HD who test positive for HCV antibody may be allowed to enroll at the discretion of the Principal Investigator if their liver function tests are not otherwise clinically significant;
  • Has donated blood or has had an acute loss of blood (˃500 mL) during the 3 months prior to study drug administration;
  • Previous administration of any [14C] labeled drug substance within 1 year of study drug administration;
  • Has irregular bowel habits. "Irregular" being defined for the purpose of this study as NOT having a bowel movement at least every 2 days.)
  • Has been involved in an occupation that requires monitoring for radiation exposure (eg, X-ray technician);

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03947970


Locations
Layout table for location information
United States, Texas
Cara Therapeutics Study Site
San Antonio, Texas, United States, 78217
Sponsors and Collaborators
Cara Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Frédérique Menzaghi, PhD Cara Therapeutics

Layout table for additonal information
Responsible Party: Cara Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03947970     History of Changes
Other Study ID Numbers: CR845-100302
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cara Therapeutics, Inc.:
Hemodialysis
Difelikefalin
Dialysis
CR845
CKD
ESRD (end stage renal disease)
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency